Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

We conducted a Phase I randomized, dose-escalation, route-comparison trial of MVA-CMDR, a candidate HIV-1 vaccine based on a recombinant modified vaccinia Ankara viral vector expressing HIV-1 genes env/gag/pol. The HIV sequences were derived from circulating recombinant form CRF01_AE, which predomin...

Full description

Bibliographic Details
Main Authors: Jeffrey R Currier, Viseth Ngauy, Mark S de Souza, Silvia Ratto-Kim, Josephine H Cox, Victoria R Polonis, Patricia Earl, Bernard Moss, Sheila Peel, Bonnie Slike, Somchai Sriplienchan, Prasert Thongcharoen, Robert M Paris, Merlin L Robb, Jerome Kim, Nelson L Michael, Mary A Marovich
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-11-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2981570?pdf=render

Internet

http://europepmc.org/articles/PMC2981570?pdf=render

Similar Items